Newsroom – Freya

The Freya Newsroom

Find out the latest about Freya. Announcements, press coverage, and company info—it’s all here.

"Women's health biotech to move lead compound into IVF patients after early-stage win"

"…has the potential of becoming the first targeted therapy for the IVF population with vaginal dysbiosis."

"…Freya and a major U.S. clinic, Boston IVF, support the concept of lower pregnancy rates in women with a dysbiotic inflammatory vaginal microbiome…"

"Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis"

"Freya is also developing candidates to tackle preterm birth and infertility caused by endometriosis."

"The findings show promise for improving fertility outcomes, particularly in in vitro fertilization (IVF) procedures."

"A former WHO epidemiologist is applying lessons learned during the Ebola epidemic … at the forefront of women’s health: the reproductive microbiome."

"Freya Biosciences, a Danish and US biotech named after the Norse goddess of fertility, has raised a $38 million Series A."

Press releases

12th December, 2023

Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies

Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.

27th June, 2023

Freya Biosciences Announces Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic.